Engineered Recombinant Single Chain Variable Fragment of Monoclonal Antibody Provides Protection to Chickens Infected with H9N2 Avian Influenza

Lukosaityte, Deimante; Sadeyen, Jean-Rémy; Shrestha, Angita; Sealy, Joshua E; Bhat, Sushant; Chang, Pengxiang; Digard, Paul; Iqbal, Munir

doi:10.3390/vaccines8010118

Cited by 11 publications

(9 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recombinant S and RBD proteins were produced and purified as previously described (Lukosaityte et al, 2020). Briefly, expression cassettes containing SARS-CoV-2 S and RBD nucleotide sequences were codon optimized for Drosophila melanogaster Schneider 2 (S2) cells.…”

Section: Star+methodsmentioning

confidence: 99%

Immunogenicity and protective efficacy of an intranasal live-attenuated vaccine against SARS-CoV-2

Park¹,

Oladunni²,

Rohaim³

et al. 2021

iScience

Self Cite

View full text Add to dashboard Cite

Global deployment of an effective and safe vaccine is necessary to curtail the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we evaluated a Newcastle disease virus (NDV)-based vectored-vaccine in mice and hamsters for its immunogenicity, safety and protective efficacy against SARS-CoV-2. Intranasal administration of recombinant (r)NDV-S vaccine expressing spike (S) protein of SARS-CoV-2 to mice induced high levels of SARS-CoV-2-specific neutralizing immunoglobulin A (IgA) and IgG2a antibodies and T cell-mediated immunity. Hamsters immunised with two doses of vaccine showed complete protection from lung infection, inflammation, and pathological lesions following SARS-CoV-2 challenge. Importantly, administration of two doses of intranasal rNDV-S vaccine significantly reduced the SARS-CoV-2 shedding in nasal turbinate and lungs in hamsters. Collectively, intranasal vaccination has the potential to control infection at the site of inoculation, which should prevent both clinical disease and virus transmission to halt the spread of the COVID-19 pandemic.

show abstract

Section: Star+methodsmentioning

confidence: 99%

Immunogenicity and protective efficacy of an intranasal live-attenuated vaccine against SARS-CoV-2

Park¹,

Oladunni²,

Rohaim³

et al. 2021

iScience

Self Cite

View full text Add to dashboard Cite

show abstract

“…Recombinant S and RBD proteins were produced and purified as previously described 65 . Briefly, expression cassettes containing SARS-CoV-2 S and RBD nucleotide sequences were codon optimized for Drosophila melanogaster Schneider 2 (S2) cells.…”

Section: Methodsmentioning

confidence: 99%

Immunogenicity and Protective Efficacy of an Intranasal Live-attenuated Vaccine Against SARS-CoV-2 in Preclinical Animal Models

Park

Oladunni

Rohaim

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

The global deployment of an effective and safe vaccine is currently a public health priority to curtail the coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we evaluated a Newcastle disease virus (NDV)-based intranasal vectored-vaccine in mice and hamsters for its immunogenicity, safety and protective efficacy in challenge studies with SARS-CoV-2. The recombinant (r)NDV-S vaccine expressing spike (S) protein of SARS-CoV-2 administrated via intranasal route in mice induced high levels of SARS-CoV-2-specific neutralizing immunoglobulin A (IgA) and IgG2a antibodies and T cell-mediated immunity. Hamsters vaccinated with two doses of vaccine showed complete protection from clinical disease including lung infection, inflammation, and pathological lesions after SARS-CoV-2 challenge. Importantly, a single or double dose of intranasal rNDV-S vaccine completely blocked SARS-CoV-2 shedding in nasal turbinate and lungs within 4 days of vaccine administration in hamsters. Taken together, intranasal administration of rNDV-S has the potential to control infection at the site of inoculation, which should prevent both the clinical disease and transmission to halt the spread of the COVID-19 pandemic.

show abstract

“…Method 1: This method was used to produce SARS-CoV-2 S protein, as described previously (28,29). Briefly, the expression cassettes containing SARS-CoV-2 S nucleotide sequences of BetaCov/Wuhan/WH04/2020 (accession number EPI-ISL-406801) were retrieved from the Global Initiative on Sharing All Influenza Data (GISAID) database.…”

Section: Development Of Elisa For Detection Of Antibodies To S and Rbd Proteins Of Sars-cov-2mentioning

confidence: 99%

Presence of Antibodies to SARS-CoV-2 in Domestic Cats in Istanbul, Turkey, Before and After COVID-19 Pandemic

et al. 2021

Self Cite

View full text Add to dashboard Cite

Recent studies demonstrated that domestic cats can be naturally and experimentally infected with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). This study was performed to investigate the presence of SARS-CoV-2-specific antibodies within the domestic cat population in Istanbul, Turkey, before the coronavirus disease 2019 (COVID-19) and during the COVID-19 pandemic. Overall, from 155 cat sera analyzed, 26.45% (41/155) tested positive in the spike protein-ELISA (S-ELISA), 28.38% (44/155) in the receptor-binding domain-ELISA (RBD-ELISA), and 21.9% (34/155) in both, the S- and RBD-ELISAs. Twenty-seven of those were also positive for the presence of antibodies to feline coronavirus (FCoV). Among the 34 SARS-CoV-2-positive sera, three of those were positive on serum neutralization assay. Six of the 30 cats before COVID-19 and 28 of the 125 cats during COVID-19 were found to be seropositive. About 20% of ELISA-positive cats exhibited mainly respiratory, gastrointestinal, and renal signs and skin lesions. Hematocrit, hemoglobin, white blood cells, lymphocyte, and platelet numbers were low in about 30% of ELISA-positive cats. The number of neutrophils and monocytes were above normal values in about 20% of ELISA-positive cats. The liver enzyme alanine aminotransferase levels were high in 23.5% ELISA-positive cats. In conclusion, this is the first report describing antibodies specific to SARS-CoV-2 antigens (S and RBD) in cats in Istanbul, Turkey, indicating the risk for domestic cats to contract SARS-CoV-2 from owners and/or household members with COVID-19. This study and others show that COVID-19-positive pet owners should limit their contact with companion animals and that pets with respiratory signs should be monitored for SARS-CoV-2 infections.

show abstract

Engineered Recombinant Single Chain Variable Fragment of Monoclonal Antibody Provides Protection to Chickens Infected with H9N2 Avian Influenza

Cited by 11 publications

References 60 publications

Immunogenicity and protective efficacy of an intranasal live-attenuated vaccine against SARS-CoV-2

Immunogenicity and protective efficacy of an intranasal live-attenuated vaccine against SARS-CoV-2

Immunogenicity and Protective Efficacy of an Intranasal Live-attenuated Vaccine Against SARS-CoV-2 in Preclinical Animal Models

Presence of Antibodies to SARS-CoV-2 in Domestic Cats in Istanbul, Turkey, Before and After COVID-19 Pandemic

Contact Info

Product

Resources

About